secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001193125-22-279108
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica Q3 net income $83K; reiterates VP-102 NDA resubmission in Q1 2023
-------------------------------------------------------------------------

- Q3 GAAP net income of $83K ($0.00/sh) vs net loss of $12.8M in Q3 2021; non-GAAP net income $2.9M ($0.07/sh).
- License revenue of $8.3M from Torii milestone; cash, equivalents and marketable securities total $39.5M.
- Reiterates plan to resubmit NDA for VP-102 (molluscum contagiosum) in Q1 2023.
- Phase 2 trial of VP-LTX-315 (basal cell carcinoma) Part 1 expected to conclude in Q1 2023.
- R&D and G&A expenses declined vs prior year due to reduced headcount and lower CMC costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312522279108/0001193125-22-279108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312522279108/d397144d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-279108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer